Nicotinic acetylcholine receptor-based blockade: Applications of molecular targets for cancer therapy

Chih Hsiung Wu, Chia Hwa Lee, Yuan Soon Ho

研究成果: 雜誌貢獻回顧型文獻

71 引文 斯高帕斯(Scopus)

摘要

The nicotinic acetylcholine receptor (nAChR) was first characterized in 1970 as a membrane receptor of a neurotransmitter and an ion channel. nAChRs have been shown to be involved in smoking-induced cancer formation in multiple types of human cancer cells. In vitro and in vivo animal studies have shown that homopentameric nAChR inhibitors, such as methyllycaconitine and α-Bgtx, can attenuate nicotine-induced proliferative, angiogenic, and metastatic effects in lung, colon, and bladder cancer cells. Recent publications have shown that α9-nAChR is important for breast cancer formation, and in many in vivo studies, α9-nAChR-specific antagonists (e.g., α-ImI, α-ImI, Vc1.1, RgIA, and It14a) produced an analgesic effect. Vc1.1 functions in a variety of animal pain models and currently has entered phase II clinical trials. For cancer therapy, natural compounds such as garcinol and EGCG have been found to block nicotine- and estrogen-induced breast cancer cell proliferation through inhibition of the α9-nAChR signaling pathway. A detailed investigation of the carcinogenic effects of nAChRs and their specific antagonists would enhance our understanding of their value as targets for clinical translation.
原文英語
頁(從 - 到)3533-3541
頁數9
期刊Clinical Cancer Research
17
發行號11
DOIs
出版狀態已發佈 - 六月 1 2011

    指紋

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

引用此